Chiesi

News

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Patients

Protecting continuity of care through sustainable respirator...

More attention is being paid to how care can be delivered in ways that maintain continuity for patients while also being environmentally responsible.

News

England poised to roll out drug for rare eye disease LHON

Patients in England with rare eye disorder LHON will finally get access to a Chiesi drug that has been available in the rest of the UK for years.

Digital

Digital health technologies and rare diseases: Enhancing the...

This pre-recorded webinar was fully funded by Chiesi GRD and hosted by pharmaphorum. Professor Maurizio Scarpa received an honorarium for his participation and contribution to this webinar.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Linear visual illustration of nodes in an arrow shape

Enabling Digitally Enhanced Care for Rare Diseases in Europe

Integrating AI and Connected Care Technologies in Lysosomal Storage Disease Patient Journeys

News

Chiesi backs growth plans with a €430m new plant in Italy

Fast-growing pharma group Chiesi has revealed plans to spend €430m on a new therapeutics manufacturing facility at its site in Milan.

Chiesi signs $1.9bn deal to buy KalVista and its HAE drug

Protecting continuity of care through sustainable respirator...

England poised to roll out drug for rare eye disease LHON

Digital health technologies and rare diseases: Enhancing the...

Enabling Digitally Enhanced Care for Rare Diseases in Europe

Chiesi backs growth plans with a €430m new plant in Italy

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Chiesi

Editor's Picks